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Abstract
Treatment of susceptible rats with dopaminergic agonists that reduce prolactin release decreases
both severity and duration of clinical signs of experimental allergic encephalomyelitis (EAE). To
assess to what extent the presence of an ectopic pituitary (that produces an increase in plasma
prolactin levels mainly derived from the ectopic gland) affects EAE, 39 male Lewis rats were
submitted to pituitary grafting from littermate donors. Another group of 38 rats was sham-
operated by implanting a muscle fragment similar in size to the pituitary graft. All rats received
subcutaneous (s.c.) injections of complete Freund's adjuvant (CFA) plus spinal cord homogenate
(SCH) and were monitored daily for clinical signs of EAE. Animals were killed by decapitation on
days 1, 4, 7, 11 or 15 after immunization and plasma was collected for prolactin RIA. In a second
experiment, 48 rats were immunized by s.c. injection of a mixture of SCH and CFA, and then
received daily s.c. injections of bromocriptine (1 mg/kg) or saline. Groups of 8 animals were killed
on days 8, 11 or 15 after immunization and plasma prolactin was measured. Only sham-operated
rats exhibited clinical signs of the disease when assessed on day 15 after immunization. A
progressive decrease in plasma prolactin levels was observed in pituitary-grafted rats, attaining a
minimum 15 days after immunization, whereas plasma prolactin levels were increased during the
course of the disease in sham-operated rats. Plasma prolactin levels were higher in pituitary-grafted
rats than in sham-operated rats 1 day after immunization, but lower on days 7, 11 and 15 after
immunogen injection. Further supporting a correlation of suppressed prolactin levels with absence
of clinical signs of EAE, rats that were administered the dopaminergic agonist bromocriptine
showed very low plasma prolactin levels and did not exhibit any clinical sign of EAE. These results
indicate that low circulating prolactin levels coincide with absence of clinical signs of EAE in Lewis
rats.
Findings
Experimental allergic encephalomyelitis (EAE) is one of
best-studied models of autoimmune disease, and is char-
acterized by an autoimmune attack on CNS myelin medi-
ated by neural autoantigen-specific T helper cells [1]. EAE
is currently the best available animal model of human
multiple sclerosis. During induction of EAE, autoreactive
T-cells are activated in the periphery by subcutaneous
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injection of either spinal cord homogenate (SCH) or CNS
antigens, which may include myelin basic protein, myelin
oligodendrocyte glycoprotein, or proteolipid protein or
their peptides [2]. About 10 days after the combined injec-
tion of complete Freund adjuvant (CFA) and spinal cord
homogenate (SCH), susceptible rats (e.g., Lewis rats)
develop a progressive paralysis associated with CNS
demyelinization. Activated, autoreactive T-cells access the
CNS and, in the presence of competent antigen presenting
cells, are further activated and induce a local inflamma-
tory response. In most such models, the T helper 1 (Th1)
subset of T-cells has been implicated in the induction
phase of EAE.
It is well established that prolactin is an important modu-
lator of the immune system through an effect that is
exerted in part on the cellular arm of immune defense
involving Th1 cytokines [3,4]. Factors that cause hypopro-
lactinemia are generally associated with reduced immu-
nocompetence, whereas prolactin administration restores
immunocompetence in hypophysectomized rats or bro-
mocriptine-treated rats [5-7]. On the other hand, signifi-
cant immune-suppressive effects of prolactin have been
noticed: several investigators have reported that prolactin
decreases natural killer cell migration and activity and
reduces lymphocyte proliferative capacity and cytokine
release in rodents [7-9]. Of relevance to EAE is the obser-
vation that treatment of animals with dopaminergic ago-
nists which reduce prolactin release decreases both
severity and duration of clinical signs of the disease
[10,11].
Since changes in prolactin secretion could modulate EAE
symptomatology, we wished to assess to what extent the
presence of an ectopic pituitary, producing an increase in
plasma prolactin levels mainly derived from the ectopic
gland [12], would affect EAE. The consequence of inhibit-
ing prolactin secretion by injecting the dopaminergic ago-
nist bromocriptine was also assessed.
Male Lewis rats (6 weeks old, 140–170 g) were purchased
from Charles River S.A., Spain, and were housed under
standard conditions of controlled light (12:12 h light/
dark schedule, light on at 0800 h) and temperature (22 ±
2°C). All experiments were conducted in accordance with
the guidelines of the International Council for Laboratory
Animal Science (ICLAS). Protocols were approved by the
Institutional Animals Ethics Committee. Spinal cord,
obtained from adult Wistar rats, was homogenized in PBS
buffer at a concentration of 1 mg/ml to serve as an immu-
nogen (SCH).
Two experiments were performed. In experiment 1, 39
rats were subjected to pituitary grafting from littermate
donors. Animals were anesthetized with 2.5% tribro-
moethanol in saline (1 ml/100 g body weight). Another
group of 38 rats of the same age was sham-operated (by
implanting a muscle fragment of a size similar to the pitu-
itary graft) to be used as a control group. Rats were left
undisturbed for 4 weeks – i.e., until the time at which
increased prolactin levels in pituitary grafted animals
attains a plateau [13] – at the end of which time all ani-
mals were immunized by subcutaneous (s.c.) injection of
a mixture of SCH and CFA containing Mycobacterium
tuberculosis H37Ra (5 mg/ml; Difco Laboratories,
Detroit, Michigan) (v/v) in a final volume of 200 μl. Ani-
mals were monitored daily for clinical signs of EAE using
the following assessment scale: 0, normal; 0.5, loss of
tonicity in distal half of tail; 1, piloerection; 2, total loss of
tail tonicity; 3, hind leg paralysis; 4, paraplegia; and 5,
moribund [14]. The rats were killed by decapitation on
days 1, 4, 7, 11 or 15 after immunization (7–8 animals per
group) and blood was collected from a trunk wound into
heparinized tubes and was centrifuged. Plasma was col-
lected and stored at -20°C until further analysis. Visual
assessment of the grafts at the time of sacrifice did not
show any gross differences between groups.
In experiment 2, 48 male Lewis rats were immunized with
SCH plus CFA mixture, and then received daily s.c. injec-
tions of bromocriptine (1 mg/kg) or saline (n = 24 each).
Animals were monitored daily for clinical signs of EAE
and were killed by decapitation on day 8, 11 or 15 after
immunization (8 animals per group), and blood was col-
lected from a trunk wound.
Plasma prolactin levels were measured by a homologous
specific double antibody RIA [15], using materials kindly
supplied by the NIDDK's National Hormone and Pitui-
tary Program and Dr. A. Parlow (Harbor UCLA Medical
Center, Torrance CA 90509). The intra- and interassay
coefficients were 6–8%. Sensitivity of the RIA was 40 pg/
ml using the NIDDK rat prolactin RP-3 standard. Results
were expressed as pg/ml of plasma. Statistical analysis of
results was performed by employing either Student's t test,
a factorial analysis of variance (ANOVA), or a one-way
ANOVA followed by a Student-Newman-Keuls test.
Figure 1 depicts the results of both experiments. The evo-
lution of clinical scores of EAE in control and pituitary-
grafted rats is shown in the upper left panel. Only sham-
operated rats exhibited clinical signs of the disease when
assessed on day 15 after immunization. Clinical scoring at
this state of disease did not differ from that previously
reported, using similar conditions, for both rats [16] and
mice [17]. Prolactin levels in both experimental groups
are shown in the lower left panel. A significant interaction
"treatment × time" was found in the factorial ANOVA, i.e.
plasma prolactin levels were higher in pituitary-grafted
rats than in sham-operated rats 1 day after immunizationJournal of Neuroinflammation 2006, 3:20 http://www.jneuroinflammation.com/content/3/1/20
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and lower on days 7, 11 and 15 after immunogen injec-
tion (p < 0.001) (lower left panel). A progressive decrease
in plasma prolactin levels was observed in pituitary-
grafted rats, attaining a minimum 15 days after immuni-
zation (p < 0.01). In contrast, prolactin levels were
increased during the course of the disease in sham-oper-
ated rats (p < 0.05). This increase in prolactin levels was
presumably a response to the administration of CFA.
Although the clinical onset of inflammatory disease fol-
lowing CFA occurs between days 12 and 15 after injection,
the increase in plasma prolactin is already demonstrable
at an early phase of the disease [18,19].
Mild hyperprolactinemia has been found to enhance sev-
eral autoimmune diseases, including systemic lupus ery-
thematosus, rheumatoid arthritis and autoimmune
thyroiditis [6,7,20]. In studies of EAE, prolactin levels
have been found to be elevated before the onset and dur-
ing the disease [21], as observed in sham-operated ani-
mals in the present study. Therefore, a feasible
Effect of changing plasma prolactin levels on clinical signs of EAE in rats Figure 1
Effect of changing plasma prolactin levels on clinical signs of EAE in rats. Two experiments were performed. In experiment 1 
(left upper and lower panels), 77 male Lewis rats were subjected either to pituitary grafting from littermate donors (n = 39) or 
to sham operations (n = 38); all were then immunized by s.c. injection of a mixture of spinal cord homogenate (SCH) and com-
plete Freund's adjuvant (CFA) as described in Methods. Rats were monitored daily for clinical signs of EAE. Groups of 7–8 rats 
were killed by decapitation on day 1, 4, 7, 11 or 15 after immunization. In experiment 2 (right upper and lower panels), 48 male 
Lewis rats were immunized with SCH plus CFA mixture, and then received daily s.c. injections of bromocriptine (1 mg/kg) or 
saline (n = 24 each). Groups of 8 rats were killed by decapitation on day 8, 11 or 15 after immunization. Prolactin levels were 
measured by RIA. Data are shown as means ± SEM. ** p < 0.01 vs. grafted rats at each time interval, Student's t test. Super-
scripts designate significant differences among time intervals within the same experimental group, a p < 0.01 vs. sham-operated 
rats on days 7, 11 or 15; b p < 0.05 vs. pituitary-grafted rats on day 1; c p < 0.05 vs. pituitary-grafted rats on days 4 or 7, p < 0.01 
vs. pituitary-grafted rats on day 1, one-way ANOVA, Student-Newman-Keuls test.Journal of Neuroinflammation 2006, 3:20 http://www.jneuroinflammation.com/content/3/1/20
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explanation for the lack of clinical signs of EAE on day 15
after immunization in pituitary-grafted rats is a relative
lack of prolactin.
Further supporting the correlation of suppressed prolactin
levels with absence of clinical signs of EAE is the observa-
tion that rats administered the dopaminergic agonist bro-
mocriptine did not exhibit any clinical sign of disease
(Fig. 1, upper right panel). Bromocriptine treatment was
very effective in preventing prolactin release at all exam-
ined time points (p < 0.001) (Fig. 1, lower right panel).
In summary, these results indicate that low circulating
prolactin levels coincide with absence of clinical signs of
EAE in Lewis rats. Since the presence of an ectopic pitui-
tary would normally be expected to lead to increased
plasma prolactin levels, further studies are needed to
unravel why prolactin production by renal pituitary grafts
is suppressed during EAE development. These results also
confirm previous findings that treatment with dopamin-
ergic agonists induces a reduction of prolactin levels
accompanied by amelioration of the neurological signs of
EAE [10,11]. The effects of dopaminergic agents could be
related to their ability to lower prolactin concentrations
and/or to a neuroprotective action of the drugs.
Caution should be taken in extrapolating these results to
human disease as monophasic EAE, particularly in the
Lewis rat model, shares only some aspects of human mul-
tiple sclerosis. Indeed, contradictory results have been
published on the occurrence of hyperprolactinemia in
multiple sclerosis patients, with some studies finding
increased prolactin levels [22-24] while others do not [25-
27].
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